Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C

Lancet

Volumn 350, Issue 9089, 1997, Pages 1425-1431

  Darby, Sarah C ^a   Ewart, David W ^a   Giangrande, Paul L F ^b   Spooner, Rosemary J D ^b   Rizza, Charles R ^b   Dusheiko, Geoffrey M ^c   Lee, Christine A ^c   Ludlam, Christopher A ^d   Preston, F Eric ^e  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CANCER RISK; CHILD; CONTAMINATION; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LIVER CANCER; LIVER DISEASE; MALE; MORTALITY; PRIORITY JOURNAL; RISK; UNITED KINGDOM; VIRUS INACTIVATION;

EID: 0031583763     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)05413-5     Document Type: Article

References (33)

1. Fletcher ML, Trowell JM, Craske J, et al. Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients. BMJ 1983; 287: 1754-57.
2. Kernoff PBA, Lee CA, Karayiannis P, et al. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 1985; 60: 469-79.
3. Watson HG, Ludlam CA, Rebus S, et al. Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates. Br J Haematol 1992; 80: 514-18.
4. Mauser-Bunschoten BP, Bresters D, van Drimmeten AA, et al. Hepatitis C infection and viremia in Dutch hemophilia patients. J Med Virol 1995; 45: 241-46.
5. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: volume 59, hepatitis viruses. France: International Agency for Research on Cancer, 1994.
6. Telfer P, Sabin C, Devereux H, et al. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994; 87: 555-61.
7. Makris M, Preston FE, Rosendaal FR, et al. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996; 94: 746-52.
8. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality before and after HIV infection in the complete UK population of haemophiliacs. Nature 1995; 377: 79-82.
9. Darby SC, Ewart DW, Giangrande PLF, et al. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996; 347: 1573-79.
10. World Health Organization. Manual of the international statistical classification of diseases, injuries, and causes of death: ninth revision, Geneva: WHO, 1977.
11. Breslow NE, Day NE. Statistical methods in cancer research: vol II; the design and analysis of cohort studies. Lyon: IARC, 1987.
12. Rizza CR, Spooner RJD. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom. BMJ 1983; 286: 929-33.
13. AIDS group of the United Kingdom Haemophilia Centre Directors with the Co-operation of the UK Haemophilia Centre Directors. Seropositivity for HIV in UK haemophiliacs. Philos Trans R Soc Lond Biol Sci 1989; 325: 179-83.
14. Report of the Medical Research Council's Blood Transfusion Research Committee Working Party on the Cryoprecipitate Method of Preparing AHF Concentrates. Factor VIII concentrates made in the United Kingdom and the treatment of haemophilia based on studies made during 1969-72. Br J Haematol 1974; 27; 391-405.
15. Sherlock S, Dooley J. Diseases of the liver and biliary system, 9th edn. Oxford: Blackwell Scientific Publications, 1993: 260-92.
16. Lee CA, Kernoff PBA, Karayiannis P, et al. Interferon therapy for chronic non-A non-B and chronic delta liver disease in haemophilia. Br J Haematol 1989; 72: 235-38.
17. Jarvis LM, Davidson F, Hanley JP, et al. Infection with hepatitis G virus among recipients of plasma products. Lancet 1996; 348: 1352-55.
18. Mannucci PM, Gdovin S, Cringen A, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactive viruses. Ann Intern Med 1994; 120: 1-7.
19. Mannucci PM, Gringeri A, Santagostino E, et al. Low risk of transmission of hepatitis E virus by large-pool coagulation factor concentrates. Lancet 1994; 343: 597-98.
20. Telfer PT, Devereux H, Savage K, et al. Chronic hepatitis C virus infection in haemophilic patients: clinical significance of viral genotype. Thromb Haemost 1995; 74: 1259-64.
21. Preston FE, Jarvis LM, Makris M, et al. Heterogeneity of hepatitis C virus genotypes in hemophilia: relationship with chronic liver disease. Blood 1995; 85: 1259-62.
22. Jarvis LM, Watson HG, McOmish F, et al. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis 1994; 170: 1018-22.
23. Colombo M, Mannucci PM, Brettler DB, et al. Hepatocellular carcinoma in hemophilia. Am J Hematol 1991; 37: 243-46.
24. Poynard T, Bedossa P, Opolon P, et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
25. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331: 1607-11.
26. Telfer PT, Brown D, Devereux H, et al. HCV RNA levels and HIV infection: evidence for a viral interaction in haemophilic patients. Br J Haematol 1994; 88: 397-99.
27. Eyster ME, Fried MW, Di-Bisceglie AM, et al. Increasing hepatitis C virus RNA levels in haemophiliacs: relationship to human immunodeficiency virus infection and liver disease: multicentre hemophilia cohort study. Blood 1994; 84: 1020-23.
28. Eyster ME, Diamondstone LS, Lien J-M, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1993; 6: 602-10.
29. Tong MJ, El-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-66.
30. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-55.
31. Colombo M, De Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-80.
32. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-association non-A, non-B hepatitis. N Engl J Med 1992; 327: 1906-11.
33. Tuveri R, Rothschild C, Pol S, et al. Hepatitis C virus genotypes in French haemophiliacs: kinetics and reappraisal of mixed infections. J Med Virol 1997; 51: 36-41.